Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NSSC +22.7%, PDD +8.6%, SSL +7.3%
Other news:
- VTLE +11.9% (report Crescent in advanced talks to acquire VTLE, according to Reuters)
- LZM +4.7% (files for 2.5 mln share common stock offering by selling shareholder)
- ETHZ +3.6% (files mixed securities shelf offering)
- IMAB +2.8% (announces the appointment of independent directors)
- ARGX +2.7% (reports topline results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG)
- AVTR +2.6% (insider buying)
- TBPH +2.4% (completes enrollment in Phase 3 CYPRESS study of Ampreloxetine)
- MLKN +2.1% (President Trump announces major tariff investigation on furniture imports; co has less exposure)
- LZB +1.9% (President Trump announces major tariff investigation on furniture imports; co has less exposure)
- ONC +1.8% (BeOne Medicines to sell its royalty rights on the worldwide sales, excluding China, of Amgen's (AMGN) IMDELLTRA (tarlatamab-dlle) for up to $950 million to Royalty Pharma (RPRX))
- INTC +1.5% (announces agreement with Trump Administration for US govt to take a 9.9% stake)
- STOK +1.5% (Stoke Therapeutics and Biogen (BIIB) Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress)
- ONCY +1% (files for $150 mln mixed securities shelf offering)